Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia

Charles Lawrence Loprinzi, N. M. Ellison, Daniel J Schaid, J. E. Krook, L. M. Athmann, A. M. Dose, J. A. Mailliard, P. S. Johnson, L. P. Ebbert, L. H. Geeraerts

Research output: Contribution to journalArticle

259 Citations (Scopus)

Abstract

Preliminary information has suggested that megestrol acetate leads to appetite stimulation and nonfluid weight gain in patients with breast cancer, other cancers, and AIDS. Pursuant to this, we developed a randomized, double-blind, placebo-controlled trial of megestrol acetate in patients with cancer-associated anorexia and cachexia. We randomly assigned 133 eligible patients to receive 800 mg of megestrol acetate per day or a placebo. Patients assigned to megestrol acetate more frequently reported improved appetite (P = .003) and food intake (P = .009) when compared with patients receiving the placebo. A weight gain of 15 lb or more over baseline was seen in 11 of 67 (16%) patients receiving megestrol acetate compared with one of 66 (2%) given the placebo (P = .003). Patients receiving megestrol acetate reported significantly less nausea (13% vs. 38% P = .001) and emesis (8% vs 25%, P = .009). No clinically or statistically significant toxic reactions were ascribed to megestrol acetate, with the exception of mild edema. This study convincingly demonstrated that megestrol acetate can stimulate appetite and food intake in patients with anorexia and cachexia associated with cancer, leading to significant weight gain in a proportion of such patients.

Original languageEnglish (US)
Pages (from-to)1127-1132
Number of pages6
JournalJournal of the National Cancer Institute
Volume82
Issue number13
StatePublished - 1990

Fingerprint

Megestrol Acetate
Cachexia
Anorexia
Neoplasms
Appetite
Placebos
Weight Gain
Therapeutics
Eating
Poisons
Nausea
Vomiting
Edema
Acquired Immunodeficiency Syndrome
Breast Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Loprinzi, C. L., Ellison, N. M., Schaid, D. J., Krook, J. E., Athmann, L. M., Dose, A. M., ... Geeraerts, L. H. (1990). Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Journal of the National Cancer Institute, 82(13), 1127-1132.

Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. / Loprinzi, Charles Lawrence; Ellison, N. M.; Schaid, Daniel J; Krook, J. E.; Athmann, L. M.; Dose, A. M.; Mailliard, J. A.; Johnson, P. S.; Ebbert, L. P.; Geeraerts, L. H.

In: Journal of the National Cancer Institute, Vol. 82, No. 13, 1990, p. 1127-1132.

Research output: Contribution to journalArticle

Loprinzi, CL, Ellison, NM, Schaid, DJ, Krook, JE, Athmann, LM, Dose, AM, Mailliard, JA, Johnson, PS, Ebbert, LP & Geeraerts, LH 1990, 'Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia', Journal of the National Cancer Institute, vol. 82, no. 13, pp. 1127-1132.
Loprinzi, Charles Lawrence ; Ellison, N. M. ; Schaid, Daniel J ; Krook, J. E. ; Athmann, L. M. ; Dose, A. M. ; Mailliard, J. A. ; Johnson, P. S. ; Ebbert, L. P. ; Geeraerts, L. H. / Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. In: Journal of the National Cancer Institute. 1990 ; Vol. 82, No. 13. pp. 1127-1132.
@article{2f3e73e250404adb99a6eb90b9a58550,
title = "Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia",
abstract = "Preliminary information has suggested that megestrol acetate leads to appetite stimulation and nonfluid weight gain in patients with breast cancer, other cancers, and AIDS. Pursuant to this, we developed a randomized, double-blind, placebo-controlled trial of megestrol acetate in patients with cancer-associated anorexia and cachexia. We randomly assigned 133 eligible patients to receive 800 mg of megestrol acetate per day or a placebo. Patients assigned to megestrol acetate more frequently reported improved appetite (P = .003) and food intake (P = .009) when compared with patients receiving the placebo. A weight gain of 15 lb or more over baseline was seen in 11 of 67 (16{\%}) patients receiving megestrol acetate compared with one of 66 (2{\%}) given the placebo (P = .003). Patients receiving megestrol acetate reported significantly less nausea (13{\%} vs. 38{\%} P = .001) and emesis (8{\%} vs 25{\%}, P = .009). No clinically or statistically significant toxic reactions were ascribed to megestrol acetate, with the exception of mild edema. This study convincingly demonstrated that megestrol acetate can stimulate appetite and food intake in patients with anorexia and cachexia associated with cancer, leading to significant weight gain in a proportion of such patients.",
author = "Loprinzi, {Charles Lawrence} and Ellison, {N. M.} and Schaid, {Daniel J} and Krook, {J. E.} and Athmann, {L. M.} and Dose, {A. M.} and Mailliard, {J. A.} and Johnson, {P. S.} and Ebbert, {L. P.} and Geeraerts, {L. H.}",
year = "1990",
language = "English (US)",
volume = "82",
pages = "1127--1132",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "13",

}

TY - JOUR

T1 - Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia

AU - Loprinzi, Charles Lawrence

AU - Ellison, N. M.

AU - Schaid, Daniel J

AU - Krook, J. E.

AU - Athmann, L. M.

AU - Dose, A. M.

AU - Mailliard, J. A.

AU - Johnson, P. S.

AU - Ebbert, L. P.

AU - Geeraerts, L. H.

PY - 1990

Y1 - 1990

N2 - Preliminary information has suggested that megestrol acetate leads to appetite stimulation and nonfluid weight gain in patients with breast cancer, other cancers, and AIDS. Pursuant to this, we developed a randomized, double-blind, placebo-controlled trial of megestrol acetate in patients with cancer-associated anorexia and cachexia. We randomly assigned 133 eligible patients to receive 800 mg of megestrol acetate per day or a placebo. Patients assigned to megestrol acetate more frequently reported improved appetite (P = .003) and food intake (P = .009) when compared with patients receiving the placebo. A weight gain of 15 lb or more over baseline was seen in 11 of 67 (16%) patients receiving megestrol acetate compared with one of 66 (2%) given the placebo (P = .003). Patients receiving megestrol acetate reported significantly less nausea (13% vs. 38% P = .001) and emesis (8% vs 25%, P = .009). No clinically or statistically significant toxic reactions were ascribed to megestrol acetate, with the exception of mild edema. This study convincingly demonstrated that megestrol acetate can stimulate appetite and food intake in patients with anorexia and cachexia associated with cancer, leading to significant weight gain in a proportion of such patients.

AB - Preliminary information has suggested that megestrol acetate leads to appetite stimulation and nonfluid weight gain in patients with breast cancer, other cancers, and AIDS. Pursuant to this, we developed a randomized, double-blind, placebo-controlled trial of megestrol acetate in patients with cancer-associated anorexia and cachexia. We randomly assigned 133 eligible patients to receive 800 mg of megestrol acetate per day or a placebo. Patients assigned to megestrol acetate more frequently reported improved appetite (P = .003) and food intake (P = .009) when compared with patients receiving the placebo. A weight gain of 15 lb or more over baseline was seen in 11 of 67 (16%) patients receiving megestrol acetate compared with one of 66 (2%) given the placebo (P = .003). Patients receiving megestrol acetate reported significantly less nausea (13% vs. 38% P = .001) and emesis (8% vs 25%, P = .009). No clinically or statistically significant toxic reactions were ascribed to megestrol acetate, with the exception of mild edema. This study convincingly demonstrated that megestrol acetate can stimulate appetite and food intake in patients with anorexia and cachexia associated with cancer, leading to significant weight gain in a proportion of such patients.

UR - http://www.scopus.com/inward/record.url?scp=0025302267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025302267&partnerID=8YFLogxK

M3 - Article

C2 - 2193166

AN - SCOPUS:0025302267

VL - 82

SP - 1127

EP - 1132

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 13

ER -